{
    "eid": "2-s2.0-85061855868",
    "title": "Access to medicines for breast, colorectal, and lung cancer in Thailand",
    "cover-date": "2018-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmaceutical Science",
            "@code": "3003",
            "@abbrev": "PHAR"
        }
    ],
    "keywords": [
        "Antineoplastic drug",
        "Drug access",
        "Market access",
        "Patient access"
    ],
    "authors": [
        "Pornsroung Saerekul",
        "Tharin Limsakun",
        "Puree Anantachoti",
        "Rungpetch Sakulbumrungsil"
    ],
    "citedby-count": 5,
    "ref-count": 23,
    "ref-list": [
        "Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012",
        "Cancer incidence trends in Thailand, 1989-2000",
        "Assessment of the evolution of cancer treatment therapies",
        "A history of cancer chemotherapy",
        "History, present status and future prospects of anticancer drug therapy",
        "Development and economic trends in cancer therapeutic drugs: A 5-year update 2010-2014",
        "Access to innovative oncology medicines in Europe",
        "Access to cancer drugs in Canada: Looking beyond coverage decisions",
        "Hurdles and delays in access to anti-cancer drugs in Europe",
        "Patient access to new cancer drugs in the United States and Australia",
        "Time to market and patient access to new oncology products in Italy: A multistep pathway from European context to regional health care providers",
        "Expanding access to high-cost medicines through the E2 access program in Thailand: Effects on utilisation, health outcomes and cost using an interrupted time-series analysis",
        "Challenges to orphan drugs access in eastern Europe: The case of Bulgaria",
        "Drug lag and key regulatory barriers in the emerging markets",
        "A study on drug innovation lag in Taiwan",
        "Access to cancer drugs: Are we meeting the needs of Malaysian?",
        "ISafE and the evidence based approach for essential medicines selection in Thailand"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Basking Ridge",
            "@id": "60016360",
            "affilname": "Daiichi Sankyo, Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016360",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Chulalongkorn University"
    ]
}